title: [Association of everolimus with tacrolimus during the first year after heart transplantation: initial experience].
authors: Montserrat
authors: M
authors: Cardona
authors: María Ángeles
authors: MÁ
authors: Castel
authors: Marta
authors: M
authors: Farrero
authors: Félix
authors: F
authors: Pérez-Villa
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077552:Basiliximab; D065095:Calcineurin Inhibitors; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D000068338:Everolimus; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control; D016027:Heart Transplantation; D006562:Herpes Zoster / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013283:Stomatitis, Herpetic / Q000209:etiology; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014775:Virus Activation / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000068338:Everolimus; D003404:Creatinine; D011241:Prednisone; D020123:Sirolimus; D016559:Tacrolimus